|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
The Phase III PROpel Trial in mCRPC, A Biomarker Analysis and the Detection of Mutations in HRR Genes
|
Noel Clarke, MBBS, FRCS, ChM
Noel Clarke joins Alicia Morgans in discussing an updated analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). He highlights the PROpel data that was presented at the 2022 ESMO meeting. |
|
|
|
|
|
|
|
|
|
|
|
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time?
|
Maha Hussain, MD, FACP, FASCO, and Fred Saad, MD, FRCS
Maha Hussain and Fred Saad join Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE study data and how it can be used in clinical practice.
|
|
|
|
|
|
|
|
|
|
|
|
First Results of MAGNITUDE – Niraparib With Abiraterone Acetate and Prednisone As First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer
|
Kim Chi, MD, FRCPC
Joining Alicia Morgans is Kim Chi discussing the first results of the MAGNITUDE phase 3 trial assessing niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without HRR gene alterations.
|
|
|
|
|
|
|
|
|
|
|
| Biomarker Analysis and Updated Results from the Phase III PROpel Trial of Abiraterone and Olaparib vs Abiraterone and Placebo as First-Line Therapy for Patients with mCRPC |
| Fred Saad, MD, FRCS |
| Fred Saad discusses a biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). |
|
|
|
|
|
| Detection of Mutations in Homologous Recombination Repair Genes in Tumour Tissue and Circulating Tumour DNA from Patients with Metastatic Castrate-Resistant Prostate Cancer in the Phase III PROpel Trial |
| Andrew J. Armstrong, MD, MSc |
| Andrew Armstrong presents the results of an analysis assessing tumor tissue-based and circulating tumor DNA (ctDNA)-based assessment of homologous recombination repair in patients enrolled in the Phase III PROpel trial assessing combination abiraterone and olaparib as first-line treatment in metastatic castrate-resistant prostate cancer (mCRPC). |
|
|
|
|
|
|
|
|
|
|
| Discussion of PRESTO in High-Risk Biochemically Relapsed Prostate Cancer and PROpel in mCRPC |
| Johann de Bono, MD, MSc, Ph.D., FRCP, FMedSci |
| Here, Johann De Bono discusses two key studies including “PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)” presented by Dr. Rahul Aggarwal and “Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with mCRPC” presented by Dr. Fred Saad. |
|
|
|
|
|
| Discussion - PROpel and MAGNITUDE |
| Celestia S. Higano, MD |
| Celestia Higano discusses the “Phase 3 MAGNITUDE study: First results of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with mCRPC with and without HRR gene alterations” presented by Dr. Kim Chi, and “PROpel: Phase III trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with mCRPC” presented by Dr. Fred Saad.
|
|
|
|
|
|
| Real-World Treatment Patterns Among Patients with mCRPC in the United States
|
| Elisabetta Malangone-Monaco, MS
|
| Elisabetta Malangone-Monaco presents the results of a study assessing real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States. With rapidly evolving treatment options in metastatic prostate cancer, these data can help guide the estimation of eligible patients for different clinical trials.
|
|
|
|
|
|
|
